Terms: = Breast cancer AND Ki-67 AND Clinical Outcome
98 results:
1. Clinicopathological and prognostic value of TIL and PD L1 in triple negative breast carcinomas.
Uğurluoğlu C; Yormaz S
Pathol Res Pract; 2023 Oct; 250():154828. PubMed ID: 37778126
[TBL] [Abstract] [Full Text] [Related]
2. TOP2A Expression in Pheochromocytoma and Abdominal Paraganglioma: a Marker of Poor clinical outcome?
Solhusløkk Höse K; Stenman A; Svahn F; Larsson C; Juhlin CC
Endocr Pathol; 2023 Mar; 34(1):129-141. PubMed ID: 36656469
[TBL] [Abstract] [Full Text] [Related]
3. Muscle mass loss in breast cancer patients of reproductive age (≤ 45 years) undergoing neoadjuvant chemotherapy.
Rossi F; Lambertini M; Brunetti N; De Giorgis S; Razeti MG; Calabrese M; Tagliafico AS
Radiol Med; 2023 Jan; 128(1):49-57. PubMed ID: 36536266
[TBL] [Abstract] [Full Text] [Related]
4. Bird's eye view analysis of in situ cholesterol metabolic pathways in breast cancer patients and its clinicopathological significance in their subtypes.
Kosaka S; Miyashita M; McNamala K; Nomura M; Shima H; Kawai M; Sato I; Harada-Shoji N; Ishida T; Choi MH; Sasano H
J Steroid Biochem Mol Biol; 2022 Jul; 221():106103. PubMed ID: 35367370
[TBL] [Abstract] [Full Text] [Related]
5. PD-L1 Protein Expression in Middle Eastern breast cancer Predicts Favorable outcome in Triple-Negative breast cancer.
Parvathareddy SK; Siraj AK; Ahmed SO; Ghazwani LO; Aldughaither SM; Al-Dayel F; Tulbah A; Ajarim D; Al-Kuraya KS
Cells; 2021 Jan; 10(2):. PubMed ID: 33503961
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic value of programmed cell death ligand-1 expression in breast cancer: A meta-analysis.
Zhang Y; Tian J; Qu C; Tang Z; Wang Y; Li K; Yang Y; Liu S
Medicine (Baltimore); 2020 Dec; 99(49):e23359. PubMed ID: 33285715
[TBL] [Abstract] [Full Text] [Related]
7. Patterns of biomarker expression in patients treated with primary endocrine therapy - a unique insight using core needle biopsy tissue microarray.
Parks RM; Albanghali MA; Syed BM; Green AR; Ellis IO; Cheung KL
Breast Cancer Res Treat; 2021 Feb; 185(3):647-655. PubMed ID: 33226492
[TBL] [Abstract] [Full Text] [Related]
8. Correlation of folate receptor alpha expression with clinicopathological parameters and outcome in triple negative breast cancer.
Zagorac I; Lončar B; Dmitrović B; Kralik K; Kovačević A
Ann Diagn Pathol; 2020 Oct; 48():151596. PubMed ID: 32829070
[TBL] [Abstract] [Full Text] [Related]
9. Expression of cancer stem cell markers in breast phyllodes tumor.
Kim SI; Koo JS
Cancer Biomark; 2020; 29(2):235-243. PubMed ID: 32675396
[TBL] [Abstract] [Full Text] [Related]
10. Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies.
Ma D; Jiang YZ; Xiao Y; Xie MD; Zhao S; Jin X; Xu XE; Shao ZM
Cancer; 2020 Jul; 126(14):3209-3218. PubMed ID: 32383785
[TBL] [Abstract] [Full Text] [Related]
11. clinical outcome and predictive factors for docetaxel and epirubicin neoadjuvant chemotherapy of locally advanced breast cancer.
Won HS; Kim YS; Kim JS; Chang ED; Na SJ; Whang IY; Lee DS
Korean J Intern Med; 2020 Nov; 35(6):1489-1496. PubMed ID: 32069523
[TBL] [Abstract] [Full Text] [Related]
12. Significance of glucocorticoid signaling in triple-negative breast cancer patients: a newly revealed interaction with androgen signaling.
Kanai A; McNamara KM; Iwabuchi E; Miki Y; Onodera Y; Guestini F; Khalid F; Sagara Y; Ohi Y; Rai Y; Yamaguchi R; Tanaka M; Miyashita M; Ishida T; Sasano H
Breast Cancer Res Treat; 2020 Feb; 180(1):97-110. PubMed ID: 31989378
[TBL] [Abstract] [Full Text] [Related]
13. Centromere 17 copy number gain reflects chromosomal instability in breast cancer.
Lee K; Kim HJ; Jang MH; Lee S; Ahn S; Park SY
Sci Rep; 2019 Nov; 9(1):17968. PubMed ID: 31784614
[TBL] [Abstract] [Full Text] [Related]
14. clinical prognostic evaluation of immunocytes in different molecular subtypes of breast cancer.
Zenan H; Zixiong L; Zhicheng Y; Mei H; Xiongbin Y; Tiantian W; Min D; Renbin L; Changchang J
J Cell Physiol; 2019 Nov; 234(11):20584-20602. PubMed ID: 31016756
[TBL] [Abstract] [Full Text] [Related]
15. FoxP3 gene polymorphism is associated with breast cancer in Iranian patients.
Arabpour F; Shafizad A; Rahimzadeh M; Norouzan M; Naderi N
Exp Oncol; 2018 Dec; 40(4):309-314. PubMed ID: 30593749
[TBL] [Abstract] [Full Text] [Related]
16. Increased Expression of c-Met is Associated with Chemotherapy-Resistant breast cancer and Poor clinical outcome.
Jia L; Yang X; Tian W; Guo S; Huang W; Zhao W
Med Sci Monit; 2018 Nov; 24():8239-8249. PubMed ID: 30444219
[TBL] [Abstract] [Full Text] [Related]
17. B7-H3 on circulating epithelial tumor cells correlates with the proliferation marker, ki-67, and may be associated with the aggressiveness of tumors in breast cancer patients.
Pizon M; Schott DS; Pachmann U; Pachmann K
Int J Oncol; 2018 Nov; 53(5):2289-2299. PubMed ID: 30226585
[TBL] [Abstract] [Full Text] [Related]
18. Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival.
Lee M; Tayyari F; Pinnaduwage D; Bayani J; Bartlett JMS; Mulligan AM; Bull SB; Andrulis IL
BMC Cancer; 2018 Jul; 18(1):750. PubMed ID: 30029633
[TBL] [Abstract] [Full Text] [Related]
19. Interleukin-13 receptor alpha 2 expression in tumor cells is associated with reduced disease-free survival in patients with luminal subtype invasive breast cancer.
Kwon HJ; Choi JE; Bae YK
Tumour Biol; 2018 Jun; 40(6):1010428318783657. PubMed ID: 29911489
[TBL] [Abstract] [Full Text] [Related]
20. A comparative study of ki-67 antigen expression between luminal A and triple-negative subtypes of breast cancer.
Borges US; Costa-Silva DR; da Silva-Sampaio JP; Escórcio-Dourado CS; Conde AM; Campelo V; Gebrim LH; da Silva BB; Lopes-Costa PV
Med Oncol; 2017 Sep; 34(9):156. PubMed ID: 28780646
[TBL] [Abstract] [Full Text] [Related]
[Next]
